Imlunestrant: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Imlunestrant. Educational only — not medical advice.
Labeled uses
INLURIYO is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1 )-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
Source: FDA labeling via NIH DailyMed (set 5bc172e4…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.